JP7064495B2 - ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体 - Google Patents

ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体 Download PDF

Info

Publication number
JP7064495B2
JP7064495B2 JP2019530790A JP2019530790A JP7064495B2 JP 7064495 B2 JP7064495 B2 JP 7064495B2 JP 2019530790 A JP2019530790 A JP 2019530790A JP 2019530790 A JP2019530790 A JP 2019530790A JP 7064495 B2 JP7064495 B2 JP 7064495B2
Authority
JP
Japan
Prior art keywords
compound
chloro
mmol
alkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2019530790A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500909A5 (enExample
JP2020500909A (ja
Inventor
リ、ジン
ジャオ、ハイボ
ワン、ジウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BeOne Medicines Ltd
Original Assignee
BeOne Medicines Ltd
Beigene Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BeOne Medicines Ltd, Beigene Ltd filed Critical BeOne Medicines Ltd
Publication of JP2020500909A publication Critical patent/JP2020500909A/ja
Publication of JP2020500909A5 publication Critical patent/JP2020500909A5/ja
Priority to JP2022070763A priority Critical patent/JP2022090051A/ja
Application granted granted Critical
Publication of JP7064495B2 publication Critical patent/JP7064495B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019530790A 2016-12-07 2017-12-07 ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体 Expired - Fee Related JP7064495B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022070763A JP2022090051A (ja) 2016-12-07 2022-04-22 ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2016/108897 2016-12-07
CN2016108897 2016-12-07
PCT/CN2017/114970 WO2018103688A1 (en) 2016-12-07 2017-12-07 IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3Kdelta INHIBITORS

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022070763A Division JP2022090051A (ja) 2016-12-07 2022-04-22 ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体

Publications (3)

Publication Number Publication Date
JP2020500909A JP2020500909A (ja) 2020-01-16
JP2020500909A5 JP2020500909A5 (enExample) 2021-01-21
JP7064495B2 true JP7064495B2 (ja) 2022-05-10

Family

ID=62491736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530790A Expired - Fee Related JP7064495B2 (ja) 2016-12-07 2017-12-07 ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体
JP2022070763A Pending JP2022090051A (ja) 2016-12-07 2022-04-22 ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022070763A Pending JP2022090051A (ja) 2016-12-07 2022-04-22 ＰＩ３Ｋδ阻害剤としてのイミダゾ［１，５－ａ］ピラジン誘導体

Country Status (16)

Country Link
US (2) US11136323B2 (enExample)
EP (1) EP3551630A4 (enExample)
JP (2) JP7064495B2 (enExample)
KR (1) KR20190091339A (enExample)
CN (2) CN114805366A (enExample)
AU (2) AU2017372377B2 (enExample)
BR (1) BR112019011847A2 (enExample)
CA (1) CA3045959A1 (enExample)
EA (1) EA201991355A1 (enExample)
IL (2) IL266986B (enExample)
MX (1) MX394882B (enExample)
NZ (1) NZ754944A (enExample)
SG (1) SG10201912192RA (enExample)
TW (2) TWI762534B (enExample)
WO (1) WO2018103688A1 (enExample)
ZA (1) ZA201903286B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3551630A4 (en) 2016-12-07 2020-07-15 Beigene, Ltd. IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
IL272988B (en) 2017-09-08 2022-08-01 Beigene Ltd Imidazo-[1,5-a]pyrazine derivatives as pi3k-delta inhibitors
US20230011916A1 (en) * 2019-11-21 2023-01-12 Beigene, Ltd. Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors
KR102344185B1 (ko) * 2020-02-26 2021-12-27 계명대학교 산학협력단 신규한 Pim 키나아제 억제제 및 이의 용도
IL308856A (en) * 2021-05-27 2024-01-01 Beigene Switzerland Gmbh SALTS OF A PI3Kdelta INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE
JP2024535799A (ja) * 2021-09-14 2024-10-02 ベイジーン スウィッツァーランド ゲーエムベーハー Ｂｔｋ阻害剤及びｐｉ３キナーゼ阻害剤の組み合わせを使用したがん治療の方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509060A (ja) 2003-10-15 2007-04-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤
JP2012524053A (ja) 2009-04-16 2012-10-11 セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ） キナーゼ阻害剤として使用するためのイミダゾピラジン類
JP2014508145A (ja) 2011-02-09 2014-04-03 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤としての複素環化合物
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013104610A1 (en) * 2012-01-10 2013-07-18 Bayer Intellectual Property Gmbh Substituted imidazopyrazines as akt kinase inhibitors
KR102229478B1 (ko) 2012-11-01 2021-03-18 인피니티 파마슈티칼스, 인코포레이티드 Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
ES2834638T3 (es) * 2013-05-30 2021-06-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
RS62713B1 (sr) 2014-08-11 2022-01-31 Acerta Pharma Bv Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
EP3551630A4 (en) * 2016-12-07 2020-07-15 Beigene, Ltd. IMIDAZO [1,5-A] PYRAZINE DERIVATIVES AS PI3KDELTA INHIBITORS
IL272988B (en) 2017-09-08 2022-08-01 Beigene Ltd Imidazo-[1,5-a]pyrazine derivatives as pi3k-delta inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509060A (ja) 2003-10-15 2007-04-12 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド イミダゾピラジンチロシンキナーゼ阻害剤
JP2012524053A (ja) 2009-04-16 2012-10-11 セントロ ナシオナル デ インベスティガシオネス オンコロヒカス（セエネイオ） キナーゼ阻害剤として使用するためのイミダゾピラジン類
JP2014508145A (ja) 2011-02-09 2014-04-03 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３キナーゼ阻害剤としての複素環化合物
WO2015058084A1 (en) 2013-10-18 2015-04-23 Medivation Technologies, Inc. Heterocyclic compounds and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REGISTRY（STN）[on line]，2008年06月06日，[検索日 2021.10.01], CAS登録番号 1025939-56-3

Also Published As

Publication number Publication date
TW202233190A (zh) 2022-09-01
EP3551630A1 (en) 2019-10-16
US20190367523A1 (en) 2019-12-05
US11136323B2 (en) 2021-10-05
AU2017372377B2 (en) 2022-03-03
IL266986B (en) 2022-03-01
IL290419A (en) 2022-04-01
US11725012B2 (en) 2023-08-15
AU2017372377A1 (en) 2019-07-18
TW201833113A (zh) 2018-09-16
JP2022090051A (ja) 2022-06-16
EP3551630A4 (en) 2020-07-15
MX2019006612A (es) 2019-08-01
IL290419B2 (en) 2023-02-01
CA3045959A1 (en) 2018-06-14
CN114805366A (zh) 2022-07-29
NZ754944A (en) 2023-02-24
MX394882B (es) 2025-03-24
WO2018103688A1 (en) 2018-06-14
TWI762534B (zh) 2022-05-01
AU2022203737A1 (en) 2022-06-23
CN110267959A (zh) 2019-09-20
CN110267959B (zh) 2022-05-27
ZA201903286B (en) 2021-01-27
SG10201912192RA (en) 2020-02-27
KR20190091339A (ko) 2019-08-05
IL266986A (en) 2019-07-31
US20220098202A1 (en) 2022-03-31
JP2020500909A (ja) 2020-01-16
IL290419B (en) 2022-10-01
EA201991355A1 (ru) 2019-11-29
BR112019011847A2 (pt) 2019-10-29

Similar Documents

Publication Publication Date Title
US11725012B2 (en) Imidazo[1,5-a]pyrazine derivatives as PI3K δ inhibitors
US11905294B2 (en) Imidazo[1,5-a]pyrazine derivatives as PI3Kδ inhibitors
JP2022517901A (ja) 環状尿素
WO2024222835A1 (en) Sarm1 modulators, preparations, and uses thereof
EA040746B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kδ
HK40088309A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
EA040339B1 (ru) ПРОИЗВОДНЫЕ ИМИДАЗО[1,5-а]ПИРАЗИНА КАК ИНГИБИТОРЫ PI3Kδ
HK40029822B (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
HK40029822A (en) Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors
HK40008309A (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors
HK40008309B (en) Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201201

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220329

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220422

R150 Certificate of patent or registration of utility model

Ref document number: 7064495

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees